Maternal use of venlafaxine near term: Correlation between neonatal effects and plasma concentrations

Therapeutic Drug Monitoring

Volumn 31, Issue 3, 2009, Pages 404-409

  Boucher, Nina ^a,b   Koren, Gideon ^c,d   Beaulac Baillargeon, Louise ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Neonates; Therapeutic drug monitoring; Venlafaxine

Indexed keywords

AMITRIPTYLINE; BENDECTIN; CARBAMAZEPINE; CLONAZEPAM; DESVENLAFAXINE; MAGNESIUM SULFATE; VENLAFAXINE;

ARTICLE; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HUMAN; MALE; NEWBORN; NEWBORN DISEASE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; TACHYPNEA; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; PLASMA; PREGNANCY; STATISTICS AS TOPIC;

EID: 67651087297     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181a58fb4     Document Type: Article

References (37)

1. Johanson R, Chapman G, Murray D, et al. The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression. J Psychosom Obstet Gynaecol. 2000;21:93-97.
2. Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry. 1998;59(Suppl 2):29-33.
3. Moses-Kolko EL, Roth EK. Antepartum and postpartum depression: healthy mom, healthy baby. J Am Med Womens Assoc. 2004;59:181-191.
4. Levey L, Ragan K, Hower-Hartley A, et al. Psychiatric disorders in pregnancy. Neurol Clin. 2004;22:863-893.
5. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996;16:915-923.
6. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001; 24:183-197.
7. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007; 27:607-613.
8. Way CM. Safety of newer antidepressants in pregnancy. Pharmacotherapy. 2007;27:546-552.
9. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol. 2008;28:334-339.
10. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.
11. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
12. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156: 1129-1132.
13. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312-316.
14. Knoppert DC, Nimkar R, Principi T, et al. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit. 2006;28:5-7.
15. Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119:52-59.
16. Pakalapati RK, Bolisetty S, Austin MP, et al. Neonatal seizures from in utero venlafaxine exposure. J Paediatr Child Health. 2006;42:737-738.
17. Beique J, de Montigny C, Blier P, et al. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology. 2000; 39:1800-1812.
18. Beique J, de Montigny C, Blier P, et al. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. in vitro studies in the rat. Neuropharmacology. 2000;39:1813-1822.
19. Blier P, Saint-Andre E, Hebert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007;10:41-50.
20. Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154:1760-1762.
21. de Moor RA, Mourad L, ter Haar J, et al. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]. Ned Tijdschr Geneeskd. 2003;147:1370-1372.
22. Koren G, Moretti M, Kapur B. Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome. J Obstet Gynaecol Can. 2006;28:299-302.
23. Ilett KF, Kristensen JH, Hackett LP, et al. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol. 2002;53:17-22.
24. Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol. 1998;45:459-462.
25. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372-2383.
26. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
27. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17:801-806.
28. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579-587.
29. Fornaro E, Li D, Pan J, et al. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med. 2007;176: 1035-1040.
30. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2002;300: 355-360.
31. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002;300:361-366.
32. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002;41:959-998.
33. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720-726.
34. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352:1112-1120.
35. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28:205-214.
36. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187:361-365.
37. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol. 2008;23(Suppl 1):43-51.